Clinical value of serum serine protease 2 in evaluation of severity of inflammation in Crohn's disease
Objective:To assess the value of serum serine protease 2 (PRSS2) in assessing the extent and severity of inflammation in Crohn's disease (CD).Methods:This study included 51 CD patients and 16 patients with colorectal cancer admitted to Shanghai Tenth People's Hospital between August 2018 and June 2022, as well as 28 healthy subjects. The clinical data from all subjects were collected, and the serum level of PRSS2 was measured by enzyme-linked immunosorbent assay (ELISA). The relationship between PRSS2 levels and clinical pathological features was examined. The diagnostic value of PRSS2 in determining the severity of CD inflammation was assessed by binary logistic regression analysis.Results:Serum PRSS2 levels increased with the deterioration of CD from remission stage to active stage. The PRSS2 level was significantly higher in severe active CD than in CD in the remission stage and moderate active stage (P<0.05). Correlation analysis showed that there was a significant correlation between PRSS2 and C-reactive protein (r=0.7013, P=0.0001) and Crohn's disease activity index (r=0.4703, P=0.0009). Receiver operating characteristic (ROC) curve analysis showed that the area under the ROC curve (AUC) of the PRSS2 level in distinguishing moderately active versus severely active CD was 0.7756 (95% confidence interval [CI]: 0.6085-0.9428, P=0.0062), and it was 0.8643 (95%CI: 0.7418-0.9868, P=0.0002) in distinguishing CD in remission versus severely active CD.Conclusion:The findings of this study suggest that serum PRSS2 has diagnostic value for the severity of CD inflammation.
万方数据
